强化罗苏瓦斯塔丁对心室重塑和心脏功能的影响,在接受PCI的STEMI老年患者中
Yiran Qin1, Siyi Jin2, Xusen Sun1
1Department of Cardiology, Qingpu Branch of Zhongshan Hospital Affiliated to Fudan University, Shanghai, China.
Frontiers in cardiovascular medicine
|September 8, 2025
概括
在PCI后的老年STEMI患者中,密集的罗斯瓦斯塔丁治疗显著改善了心脏功能,减少了炎症和心室重塑. 高剂量的罗斯瓦斯塔丁为这些患者提供了卓越的益处.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 生物医学工程 生物医学工程
背景情况:
- 老年人的急性心肌梗塞 (AMI) 经常导致左心室 (LV) 重塑,影响预后.
- ST段升高心肌梗塞 (STEMI) 是一种关键形式的AMI,需要及时干预.
- 穿皮冠状动脉干预 (PCI) 是STEMI的标准治疗方法.
研究的目的:
- 评估强化罗斯瓦斯塔丁治疗对心室重塑标记物的影响.
- 评估PCI后老年STEMI患者对心脏功能的影响.
- 为了比较高剂量与标准剂量的罗斯瓦斯塔丁疗效.
主要方法:
- 100名接受紧急PCI的老年STEMI患者被随机分类.
- 强化组 (n=50) 接受了每天20毫克罗斯瓦斯塔丁;对照组 (n=50) 接受了每天10毫克罗斯瓦斯塔丁.
- 在8周内评估脂质样本,炎症标志物,纤维化指标和心声回声学参数.
主要成果:
- 强化使用罗斯瓦斯塔丁显著降低了炎症标志物 (CRP,IL-6,TNF-α,ICAM-1).
- 改善了心室重塑标志物 (较低的NT-proBNP,甲-3,MMP-9;较高的TIMP-4).
- 改善心脏功能 (较高的LVEF,中风体积,TDI s'-l;较低的LVESD,LVESV).
结论:
- 在PCI后的老年STEMI患者中,高剂量罗斯瓦斯塔丁治疗比标准剂量更有效.
- 密集治疗可缓解炎症,改善 LV 重塑,并增强心脏功能.
- 罗斯瓦斯塔丁治疗对这一患者队列的预后产生了积极的影响.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
943
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
943
01:28Acute Coronary Syndrome IV: Interprofessional Care
220
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
220
01:27Coronary Artery Disease V: Interprofessional Care
215
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
215
01:30Acute Coronary Syndrome III: Diagnostic Studies
219
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
219
01:26Atherosclerosis III: Management
322
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
322
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
472
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
472